Skip to main content
. 2018 Feb 21;9:122. doi: 10.3389/fphys.2018.00122

Figure 6.

Figure 6

Chronic AMPK activation by A-769662 protected against HFD-induced obesity and dysregulated glucose metabolism (A) Body weight (left) and average body weight gain (right) of chow- and HFD-fed mice during the 6-week treatment period. (B) Average food intake of chow- and HFD-fed mice during the 6-week treatment period. (C) Absolute weights of the liver, iWAT, eWAT, pWAT and BAT of chow- and HFD-fed mice after 6-week treatment. (D,E) Liver TG (D) and TC (E) levels of chow- and HFD-fed mice after 6-week treatment. (F) Fasting blood glucose was measured during the 4th week of treatment. (G,H) Intraperitoneal glucose tolerance tests of chow- and HFD-fed mice were conducted at week 4 of treatment (G). The AUC from 0 to 120 min was calculated (H). (I,J) Insulin tolerance test of chow- and HFD-fed mice were conducted at week 5 of treatment (I). The AUC from 0 to 120 min was calculated (J). Chow-Veh: mice fed a chow diet and treated with vehicle, Chow-A-769662: mice fed a chow diet and treated with A-769662, HFD-Veh: mice fed a HFD and treated with vehicle, HFD-A-769662: mice fed a HFD and treated with A-769662. Data are presented as the means ± SEM. n = 5–9. Student's t-test. *P < 0.05, **P < 0.01 compared with the indicated control group.